Nubain, Nalbuphine Newswire

Comprehensive Real-Time News Feed for Nubain, Nalbuphine (generic).

Results 1 - 11 of 11 in Nubain, Nalbuphine (generic)

  1. Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic PruritusRead the original story

    Monday Jul 14 | Hispanic Business

    The Company recently released data from its successfully completed Phase 1 trial in which Nalbuphine ER was well tolerated in hemodialysis patients and established proof-of-concept for Nalbuphine ER in treating uremic pruritus.

    Comment?

  2. Trevi Therapeutics Announces Initiation of a Pivotal Study of Nalbuphine ER in Uremic PruritusRead the original story

    Monday Jul 14 | Business Wire

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced the first patient enrolled in the pivotal study of Nalbuphine ER in hemodialysis patients with uremic pruritus .

    Comment?

  3. Boost drive against illegal drugs or face...Read the original story

    Monday Jul 7 | Sun-Star

    THE Cebu Provincial Police Office is assessing the performance of all police station chiefs in the campaign against illegal drugs.

    Comment?

  4. Trevi Therapeutics Announces $25 Million Series B Financing Led by...Read the original story

    Jun 11, 2014 | Hispanic Business

    " or the "Company"), a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, announced a Series B financing of ).

    Comment?

  5. Trevi Therapeutics Reports $25 Million Series B Financing Led by TPG BiotechRead the original story

    Jun 9, 2014 | Hispanic Business

    The Company plans to use the funding for the initiation of pivotal trials in two severe itch conditions: uremic pruritus and prurigo nodularis.

    Comment?

  6. Clinical Stage Biotech Trevi Therapeutics Brings In $25 Million Series B FinancingRead the original story

    Jun 4, 2014 | BioSpace

    Trevi Therapeutics Announces $25 Million Series B Financing Led by TPG Biotech for Development of Nalbuphine ER NEW HAVEN, Conn.-- --Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced a Series B financing of $25 million led by TPG Biotech, the life science ... (more)

    Comment?

  7. TPG Biotech leads Series B round for TreviRead the original story w/Photo

    Jun 4, 2014 | PE Hub

    Trevi Therapeutics said Wednesday that it has received $25 million in Series B financing.

    Comment?

  8. Trevi Therapeutics Announces $25 Million Series B Financing Led by...Read the original story

    Jun 3, 2014 | Venture Capital Access Online

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, today announced a Series B financing of $25 million led by TPG Biotech, the life science venture investment arm of TPG, with $15 million funded at first closing.

    Comment?

  9. Trevi Therapeutics Exhibits Poster at 2014 Annual Meeting of the...Read the original story

    May 21, 2014 | Hispanic Business

    Nalbuphine ER was dose escalated every three days from 30 mg to 240 mg BID over 17 days.

    Comment?

  10. Trevi Therapeuitcs Exhibits Poster At 2014 Annual Meeting Of TheRead the original story

    May 9, 2014 | BioSpace

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, will exhibit a poster with the results of a recently completed Phase 1 proof-of-concept study at the 2014 Annual Meeting of the Society for Investigative Dermatology in Albuquerque, NM being held May 7-10.

    Comment?

  11. Trevi Therapeutics Exhibits Poster at 2014 Annual Meeting of the...Read the original story

    May 9, 2014 | Business Wire

    Trevi Therapeutics, Inc. , a clinical stage biotechnology company developing Nalbuphine ER for chronic pruritus conditions, will exhibit a poster with the results of a recently completed Phase 1 proof-of-concept study at the 2014 Annual Meeting of the Society for Investigative Dermatology in Albuquerque, NM being held May 7-10.

    Comment?